220
Participants
Start Date
June 8, 2017
Primary Completion Date
February 15, 2021
Study Completion Date
February 17, 2022
Active Comparator: Olaparib tablets
"Olaparib~300mg Olaparib tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria."
Placebo
"Placebo~300mg placebo tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria."
Research Site, København Ø
Research Site, Leuven
Research Site, Namur
Research Site, Odense C
Research Site, Nice
Research Site, Aalborg
Research Site, Candiolo
Research Site, Torino
Research Site, Córdoba
Research Site, Caen
Research Site, A Coruña
Research Site, Rostock
Research Site, Milan
Research Site, Milan
Research Site, Milan
Research Site, Hamburg
Research Site, Plerin SUR MER
Research Site, Lübeck
Research Site, Besançon
Research Site, Brescia
Research Site, Madrid
Research Site, Madrid
Research Site, Madrid
Research Site, Málaga
Research Site, Toulouse
Research Site, Bordeaux
Research Site, Montpellier
Research Site, Bologna
Research Site, Seville
Research Site, Reggio Emilia
Research Site, Nantes
Research Site, Saint-Herblain
Research Site, Essen
Research Site, Valencia
Research Site, Valencia
Research Site, Valencia
Research Site, Petah Tikva
Research Site, Kfar Saba
Research Site, Vandœuvre-lès-Nancy
Research Site, Lille
Research Site, Frankfurt
Research Site, Clermont-Ferrand
Research Site, Wiesbaden
Research Site, Mannheim
Research Site, Lyon
Research Site, Heidelberg
Research Site, Pierre-Bénite
Research Site, Stuttgart
Research Site, Lecce
Research Site, Paris
Research Site, Paris
Research Site, Paris
Research Site, Paris
Research Site, Napoli
Research Site, Ulm
Research Site, Saint-Cloud
Research Site, Catania
Research Site, Ramat Gan
Research Site, Tel Aviv
Research Site, London
Research Site, Toronto
Research Site, Dresden
Research Site, Jena
Research Site, München
Research Site, Jerusalem
Research Site, Roma
Research Site, Oslo
Research Site, Grzepnica
Research Site, Lublin
Research Site, Olsztyn
Research Site, Poznan
Research Site, Warsaw
Research Site, Barcelona
Research Site, L'Hospitalet de Llobregat
Research Site, Madrid
Research Site, Glasgow
Research Site, Leeds
Research Site, London
Research Site, London
Research Site, Metropolitan Borough of Wirral
Research Site, Sutton
Research Site, Taunton
Lead Sponsor
European Network of Gynaecological Oncological Trial Groups (ENGOT)
OTHER
AstraZeneca
INDUSTRY